<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!-- Generated by Fujitsu XWand B0126 -->
<!-- Generated by Fujitsu Interstage XWand B0166_M01 -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:path="http://www.nupathe.com/20120331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:schemaRef xlink:type="simple" xlink:href="path-20120331.xsd" />
  <xbrli:context id="D2011Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001375200</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001375200</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2012Q1ITD">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001375200</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2005-01-07</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001375200</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001375200</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2010">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001375200</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2011Q1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001375200</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012Q1SO">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001375200</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-05-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag1" decimals="2" contextRef="D2011Q1" unitRef="USDPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag2" decimals="0" contextRef="D2012Q1" unitRef="Shares">14732582</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Tag3" decimals="0" contextRef="D2011Q1" unitRef="Shares">14553748</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Tag4" decimals="0" contextRef="D2012Q1" unitRef="Shares">14732582</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Tag5" decimals="0" contextRef="D2011Q1" unitRef="Shares">14553748</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag6" decimals="-3" contextRef="D2012Q1" unitRef="USD">25000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag7" decimals="-3" contextRef="D2011Q1" unitRef="USD">15000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="Tag8" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">280000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:GainLossOnDispositionOfAssets id="Tag9" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">-24000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:ShareBasedCompensation id="Tag10" decimals="-3" contextRef="D2012Q1" unitRef="USD">331000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag11" decimals="-3" contextRef="D2011Q1" unitRef="USD">254000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag12" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">2679000</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfFinancingCosts id="Tag13" decimals="-3" contextRef="D2012Q1" unitRef="USD">65000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts id="Tag14" decimals="-3" contextRef="D2011Q1" unitRef="USD">54000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts id="Tag15" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">5580000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag16" decimals="-3" contextRef="D2012Q1" unitRef="USD">-58000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag17" decimals="-3" contextRef="D2011Q1" unitRef="USD">1112000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag18" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">-705000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Tag19" decimals="-3" contextRef="D2012Q1" unitRef="USD">-415000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Tag20" decimals="-3" contextRef="D2011Q1" unitRef="USD">482000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Tag21" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">1552000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Tag22" decimals="-3" contextRef="D2012Q1" unitRef="USD">17000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Tag23" decimals="-3" contextRef="D2011Q1" unitRef="USD">-1448000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="Tag24" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">2014000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag25" decimals="-3" contextRef="D2012Q1" unitRef="USD">-6203000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag26" decimals="-3" contextRef="D2011Q1" unitRef="USD">-5478000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag27" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">-84552000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment id="Tag28" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">5500000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
  <us-gaap:PaymentsToAcquireOtherProductiveAssets id="Tag29" decimals="-3" contextRef="D2011Q1" unitRef="USD">536000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
  <us-gaap:PaymentsToAcquireOtherProductiveAssets id="Tag30" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">6763000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag31" decimals="-3" contextRef="D2012Q1" unitRef="USD">112000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag32" decimals="-3" contextRef="D2011Q1" unitRef="USD">28000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag33" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">603000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag34" decimals="-3" contextRef="D2012Q1" unitRef="USD">-112000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag35" decimals="-3" contextRef="D2011Q1" unitRef="USD">-564000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag36" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">-12866000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfDebt id="Tag37" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">17500000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:PaymentsOfDebtIssuanceCosts id="Tag38" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">325000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:RepaymentsOfDebt id="Tag39" decimals="-3" contextRef="D2012Q1" unitRef="USD">2170000</us-gaap:RepaymentsOfDebt>
  <us-gaap:RepaymentsOfDebt id="Tag40" decimals="-3" contextRef="D2011Q1" unitRef="USD">129000</us-gaap:RepaymentsOfDebt>
  <us-gaap:RepaymentsOfDebt id="Tag41" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">6819000</us-gaap:RepaymentsOfDebt>
  <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock id="Tag42" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">43576000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag43" decimals="-3" contextRef="D2011Q1" unitRef="USD">21000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag44" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">43593000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromConvertibleDebt id="Tag45" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">14467000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag46" decimals="-3" contextRef="D2012Q1" unitRef="USD">-2170000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag47" decimals="-3" contextRef="D2011Q1" unitRef="USD">-108000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag48" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">111992000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NatureOfOperations id="Tag49" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(1)&amp;#160;Background&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;NuPathe Inc. (the &amp;#8220;Company&amp;#8221;) is a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system. The Company was incorporated in Delaware on January&amp;#160;7, 2005 (&amp;#8220;inception&amp;#8221;) and has its principal office in Conshohocken, Pennsylvania.&amp;#160; The Company operates as a single business segment and is a development stage company.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:NatureOfOperations>
  <us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock id="Tag50" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(2)&amp;#160;Development-Stage Risks and Liquidity&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The Company has incurred losses and negative cash flows from operations since inception and has accumulated a deficit during the development stage of $109,268 as of March&amp;#160;31, 2012. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its products currently in development.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Management estimates that cash and cash equivalents of $14,574 as of March&amp;#160;31, 2012, of which $3,000 is required to be maintained under the terms of our Term Loan Facility, will be sufficient to fund operations, debt service and interest obligations into the third quarter of 2012. Additional capital will be needed by the Company to fund its operations and capital requirements beyond that point. There is no assurance that such capital will be available when needed or on acceptable terms. These factors raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings, debt financings, corporate collaboration and licensing agreements and other funding transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. Until such time as the Company is able to secure the necessary funding, it plans to continue conserving its capital resources, predominantly by focusing on activities related to NP101.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The Company is subject to those risks associated with any development-stage specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&amp;#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially successful. In addition, the Company operates in an environment of rapid technological change, and is largely dependent on the services of its employees and consultants.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="Tag51" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(3)&amp;#160;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(a)&amp;#160;Basis of Presentation&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and with the instructions to Form&amp;#160;10-Q and Article&amp;#160;10 of Regulation S-X. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, include all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules&amp;#160;and regulations of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Results for any interim period are not necessarily indicative of results for any future interim period or for the entire year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company&amp;#8217;s Annual Report on Form&amp;#160;10-K for the year ended December&amp;#160;31, 2011 filed with the SEC, which includes annual audited financial statements as of and for the year ended December&amp;#160;31, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(b)&amp;#160;Use of Estimates&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from such estimates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(c)&amp;#160;Fair Value of Financial Instruments&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Management believes that the carrying amounts of its financial instruments, including cash equivalents, prepaid expenses and other, accounts payable and accrued expenses, approximate fair value due to the short-term nature of those instruments. The carrying amount of the Company&amp;#8217;s debt obligations approximate fair value based on interest rates available on similar borrowings.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The Company follows Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) accounting guidance on fair value measurements for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 38.9pt"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt" size="2"&gt;Level 1: &lt;/font&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 38.9pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 38.9pt"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt" size="2"&gt;Level 2: &lt;/font&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Quoted prices in markets that are not active, or input which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; or&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 38.9pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 38.9pt"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt" size="2"&gt;Level 3: &lt;/font&gt;&lt;/i&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0in 0in 0pt 38.9pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The Company had Level 1 fair value measurements of its cash equivalents of $13,661 and $22,144 at March&amp;#160;31, 2012 and December&amp;#160;31, 2011, respectively.&amp;#160; The Company had no Level 2 or Level 3 fair value instruments at March&amp;#160;31, 2012 or December&amp;#160;31, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 3pt; MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(d)&amp;#160;Other Assets-Equipment Funding&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;In June&amp;#160;2010, the Company entered into an equipment funding agreement with LTS Lohmann Therapie-Systeme AG (&amp;#8220;LTS&amp;#8221;), under which the Company agreed to fund the purchase by LTS of manufacturing equipment for the Company&amp;#8217;s primary product candidate, NP101. The Company agreed to make 14&amp;#160;monthly installments to LTS that commenced in June&amp;#160;2010, according to an agreed upon payment schedule. As of March&amp;#160;31, 2012, &amp;#8364;4,970, or $6,763 based on exchange rates in effect at the time the payments were made, has been recorded as a noncurrent asset in the accompanying balance sheet. All amounts owed under this funding agreement have been paid in full as of March&amp;#160;31, 2012. Amounts capitalized under the LTS funding agreement will be amortized to cost of goods sold upon the commencement of commercial sales of NP101. If the Company were to ever cease development of NP101, amounts capitalized under this agreement would be immediately expensed.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;LTS owns the purchased equipment and is responsible for its routine and scheduled maintenance and repair and is required to use the purchased equipment solely to manufacture NP101 for the Company. The equipment funding agreement will remain in effect until the later of the completion by LTS of all installation activities or the execution of a commercial manufacturing agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(e)&amp;#160;Net Loss per Common Share&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding less the weighted-average shares subject to repurchase during the period. For all periods presented, common stock options, unvested restricted shares of common stock and stock warrants have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as of March&amp;#160;31, 2012 and 2011, as they would be anti-dilutive:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="26%" colspan="3"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;March&amp;#160;31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="70%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;2012&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;2011&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Shares underlying outstanding options to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;2,410,386&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;1,455,834&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Shares of unvested restricted stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;16,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 70%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="70%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Shares underlying outstanding warrants to purchase common stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;200,268&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;140,520&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(f)&amp;#160;Recently Issued Accounting Standards&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;In June&amp;#160;2011, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No.&amp;#160;2011-05, Comprehensive Income (Topic 220): Presentation of Comprehensive Income (&amp;#8220;ASU 2011-05&amp;#8221;). The issuance of ASU 2011-05 is intended to improve the comparability, consistency and transparency of financial reporting and to increase the prominence of items reported in other comprehensive income. The guidance in ASU 2011-05 supersedes the presentation options in ASC Topic 220 and facilitates convergence of U.S.&amp;#160;GAAP and IFRS by eliminating the option to present components of other comprehensive income as part of the statement of changes in stockholders&amp;#8217; equity and requiring that all non-owner changes in stockholders&amp;#8217; equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. ASU 2011-05 is effective for interim periods and years beginning after December&amp;#160;15, 2011. The adoption of ASU 2011-05 did not have an impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;In December&amp;#160;2011, the FASB issued ASU No.&amp;#160;2011-12, Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No.&amp;#160;2011-05 (ASU&amp;#160;2011-12). The amendments are being made to allow the FASB time to redeliberate whether to present on the face of the financial statements the effects of reclassifications out of accumulated other comprehensive income on the components of net income and other comprehensive income for all periods presented. All other requirements in ASU 2011-05 are not affected by this Update, including the requirement to report comprehensive income either in a single continuous financial statement or in two separate but consecutive financial statements. The adoption of ASU&amp;#160;2011-12 did not have an impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Tag52" contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(5)&amp;#160;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(a)&amp;#160;Warrants&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;As of March&amp;#160;31, 2012, the following warrants to purchase common stock were outstanding:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in" border="0" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;Shares&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="18%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Expiration&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="33%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;140,520&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.62%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;7.45&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;2016 through 2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Common Stock&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;59,748&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.62%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 17.14%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="17%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;7.95&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="33%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="18%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 33.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="33%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;200,268&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="18%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="3%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 18.76%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="18%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(b)&amp;#160;Stock Options&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;On January&amp;#160;3, 2012, an additional 737,429 shares of common stock were made available under the Company&amp;#8217;s 2010 Omnibus Incentive Compensation Plan, as amended and restated effective April&amp;#160;11, 2011 (the &amp;#8220;2010 Plan&amp;#8221;), pursuant to its &amp;#8220;evergreen provision&amp;#8221; bringing the total shares authorized under the 2010 Plan to 2,975,385.&amp;#160; As of March&amp;#160;31, 2012, there were 2,410,386 incentive and non-qualified stock options and 16,000 shares of restricted stock outstanding under this plan.&amp;#160; At March&amp;#160;31, 2012 there were 464,033 shares of common stock available for future grants under the 2010 Plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The following is a summary of stock option activity for the three months ended March&amp;#160;31, 2012:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 100%; BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Number&amp;#160;of&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Shares&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Weighted&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Exercise&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Price&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Weighted&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Average&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Remaining&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Contractual&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Term&amp;#160;in&amp;#160;Years&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Aggregate&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Intrinsic&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/b&gt;&lt;b&gt;&lt;font style="FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Outstanding at January&amp;#160;1, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;1,784,285&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;4.31&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;654,346&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;3.04&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Cancelled/forfeited&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;(28,245&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0.375pt; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;6.11&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Outstanding at March&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;2,410,386&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;3.95&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;8.16&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;2,433&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Vested and expected to vest at March&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;2,155,559&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;3.61&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;8.06&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;2,362&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="41%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Exercisable at March&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;1,077,472&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;2.75&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;6.83&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="10%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;1,718&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="307"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="90"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="80"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="90"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="19"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="10"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="80"&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-TOP: medium none; BORDER-RIGHT: medium none" width="7"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Of the 654,346 stock options that were granted during the three months ended March&amp;#160;31, 2012, 22,758 were granted to certain directors pursuant to an election by such directors to receive all or a portion of their cash director fees in stock options.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 25pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The aggregate intrinsic value represents the total amount by which the value of the shares of common stock subject to such options exceeds the exercise price of such options, based on the Company&amp;#8217;s closing stock price of $3.70 as of March&amp;#160;31, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Stock-based compensation expense related to stock options for the three months ended March&amp;#160;31, 2012 and 2011 was $331 and $254, respectively. As of March&amp;#160;31, 2012, there was $3,157 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 3.0 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Management calculates the fair value of stock options based upon the Black Scholes option pricing model. The following table summarizes the fair value and assumptions used in determining the fair value of stock options issued during the three months ended March&amp;#160;31, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in" border="0" cellspacing="0" cellpadding="0" width="80%"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="75%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Weighted- average fair value of stock options granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;$&amp;#160;2.11&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="75%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="75%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;Assumptions Used:&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="75%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;1.01 &amp;#8212;1.18%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="75%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Expected life in Years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;5.0 &amp;#8212; 6.1 years&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75.22%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="75%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.18%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;81.2- 81.8%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 75.22%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="top" width="75%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Dividend Yield&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="4%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.18%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="19%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;0%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.6%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The Company determined the options&amp;#8217; life based on the use of the simplified method.&amp;#160; As a newly public company, sufficient history to estimate the volatility of our common stock price is not available. The Company uses a basket of comparable public companies as a basis for the expected volatility assumption and dividend yield. The Company intends to continue to consistently apply this process using comparable companies until a sufficient amount of historical information regarding the volatility and dividend yield of the Company&amp;#8217;s share price becomes available. The risk free interest rate is based on the yield of an applicable term Treasury instrument.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(c)&amp;#160;Restricted Stock&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 49pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;The following is a summary of restricted stock activity for the three months ended March&amp;#160;31, 2012:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 86.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in" border="0" cellspacing="0" cellpadding="0" width="86%"&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="65%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Number&amp;#160;of&lt;br /&gt;
Shares&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold" size="1"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Grant&amp;#160;Date&lt;br /&gt;
Fair&amp;#160;Value&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Nonvested shares at December&amp;#160;31, 2011&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;16,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;7.73&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Forfeited/repurchased&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#8212;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="13%" colspan="2"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="HEIGHT: 0px"&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 65.38%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="65%"&gt;
&lt;p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Nonvested shares at March&amp;#160;31, 2012&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 13.84%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="13%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;16,000&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.88%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="2%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="12%"&gt;
&lt;p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;7.73&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in" bgcolor="#CCEEFF" valign="bottom" width="1%"&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 1pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 49pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;As of March&amp;#160;31, 2012, there was $96 of unrecognized compensation expense related to unvested restricted stock, which is expected to be recognized over a weighted average period of 3.1&amp;#160;years.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag53" decimals="-3" contextRef="I2012Q1" unitRef="USD">14574000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag54" decimals="-3" contextRef="I2012Q1" unitRef="USD">275000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag55" decimals="-3" contextRef="I2012Q1" unitRef="USD">14849000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag56" decimals="-3" contextRef="I2012Q1" unitRef="USD">299000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="Tag57" decimals="-3" contextRef="I2012Q1" unitRef="USD">417000</us-gaap:OtherAssetsNoncurrent>
  <path:OtherAssetsEquipmentFunding id="Tag58" decimals="-3" contextRef="I2012Q1" unitRef="USD">6763000</path:OtherAssetsEquipmentFunding>
  <us-gaap:Assets id="Tag59" decimals="-3" contextRef="I2012Q1" unitRef="USD">22328000</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag60" decimals="-3" contextRef="I2011" unitRef="USD">23059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag61" decimals="-3" contextRef="I2011" unitRef="USD">333000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag62" decimals="-3" contextRef="I2011" unitRef="USD">23392000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag63" decimals="-3" contextRef="I2011" unitRef="USD">213000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="Tag64" decimals="-3" contextRef="I2011" unitRef="USD">481000</us-gaap:OtherAssetsNoncurrent>
  <path:OtherAssetsEquipmentFunding id="Tag65" decimals="-3" contextRef="I2011" unitRef="USD">6763000</path:OtherAssetsEquipmentFunding>
  <us-gaap:Assets id="Tag66" decimals="-3" contextRef="I2011" unitRef="USD">30849000</us-gaap:Assets>
  <us-gaap:LongTermDebtCurrent id="Tag67" decimals="-3" contextRef="I2012Q1" unitRef="USD">8297000</us-gaap:LongTermDebtCurrent>
  <us-gaap:AccountsPayableCurrent id="Tag68" decimals="-3" contextRef="I2012Q1" unitRef="USD">1552000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag69" decimals="-3" contextRef="I2012Q1" unitRef="USD">2035000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag70" decimals="-3" contextRef="I2012Q1" unitRef="USD">11884000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag71" decimals="-3" contextRef="I2012Q1" unitRef="USD">3426000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:Liabilities id="Tag72" decimals="-3" contextRef="I2012Q1" unitRef="USD">15310000</us-gaap:Liabilities>
  <us-gaap:LongTermDebtCurrent id="Tag73" decimals="-3" contextRef="I2011" unitRef="USD">8412000</us-gaap:LongTermDebtCurrent>
  <us-gaap:AccountsPayableCurrent id="Tag74" decimals="-3" contextRef="I2011" unitRef="USD">1967000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Tag75" decimals="-3" contextRef="I2011" unitRef="USD">2018000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag76" decimals="-3" contextRef="I2011" unitRef="USD">12397000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtNoncurrent id="Tag77" decimals="-3" contextRef="I2011" unitRef="USD">5481000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:Liabilities id="Tag78" decimals="-3" contextRef="I2011" unitRef="USD">17878000</us-gaap:Liabilities>
  <us-gaap:PreferredStockValue id="Tag79" xsi:nil="true" contextRef="I2011" unitRef="USD" />
  <us-gaap:PreferredStockValue id="Tag80" xsi:nil="true" contextRef="I2012Q1" unitRef="USD" />
  <us-gaap:CommonStockValue id="Tag81" decimals="-3" contextRef="I2012Q1" unitRef="USD">15000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="Tag82" decimals="-3" contextRef="I2012Q1" unitRef="USD">116271000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage id="Tag83" decimals="-3" contextRef="I2012Q1" unitRef="USD">109268000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:StockholdersEquity id="Tag84" decimals="-3" contextRef="I2012Q1" unitRef="USD">7018000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag85" decimals="-3" contextRef="I2012Q1" unitRef="USD">22328000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockValue id="Tag86" decimals="-3" contextRef="I2011" unitRef="USD">15000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="Tag87" decimals="-3" contextRef="I2011" unitRef="USD">115940000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage id="Tag88" decimals="-3" contextRef="I2011" unitRef="USD">102984000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:StockholdersEquity id="Tag89" decimals="-3" contextRef="I2011" unitRef="USD">12971000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag90" decimals="-3" contextRef="I2011" unitRef="USD">30849000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="Tag91" decimals="INF" contextRef="I2012Q1" unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="Tag92" decimals="INF" contextRef="I2011" unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="Tag93" decimals="INF" contextRef="I2012Q1" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="Tag94" decimals="INF" contextRef="I2011" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="Tag95" decimals="INF" contextRef="I2012Q1" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="Tag96" decimals="INF" contextRef="I2011" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="Tag97" decimals="INF" contextRef="I2012Q1" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="Tag98" decimals="INF" contextRef="I2011" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag99" decimals="INF" contextRef="I2012Q1" unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag100" decimals="INF" contextRef="I2011" unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Tag101" decimals="INF" contextRef="I2012Q1" unitRef="Shares">90000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="Tag102" decimals="INF" contextRef="I2011" unitRef="Shares">90000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Tag103" decimals="INF" contextRef="I2012Q1" unitRef="Shares">14748582</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag104" decimals="INF" contextRef="I2012Q1" unitRef="Shares">14748582</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued id="Tag105" decimals="INF" contextRef="I2011" unitRef="Shares">14748582</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Tag106" decimals="INF" contextRef="I2011" unitRef="Shares">14748582</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromGrants id="Tag107" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">650000</us-gaap:RevenueFromGrants>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost id="Tag108" decimals="-3" contextRef="D2012Q1" unitRef="USD">3454000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag109" decimals="-3" contextRef="D2012Q1" unitRef="USD">2387000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="Tag110" decimals="-3" contextRef="D2012Q1" unitRef="USD">5841000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost id="Tag111" decimals="-3" contextRef="D2011Q1" unitRef="USD">1574000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag112" decimals="-3" contextRef="D2011Q1" unitRef="USD">1970000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="Tag113" decimals="-3" contextRef="D2011Q1" unitRef="USD">3544000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost id="Tag114" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">64712000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentInProcess id="Tag115" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">5500000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="Tag116" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">26402000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="Tag117" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">96614000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag118" decimals="-3" contextRef="D2012Q1" unitRef="USD">-5841000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="Tag119" decimals="-3" contextRef="D2012Q1" unitRef="USD">10000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense id="Tag120" decimals="-3" contextRef="D2012Q1" unitRef="USD">453000</us-gaap:InterestExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag121" decimals="-3" contextRef="D2012Q1" unitRef="USD">-6284000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:NetIncomeLoss id="Tag122" decimals="-3" contextRef="D2012Q1" unitRef="USD">-6284000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag123" decimals="-3" contextRef="D2011Q1" unitRef="USD">-3544000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="Tag124" decimals="-3" contextRef="D2011Q1" unitRef="USD">24000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense id="Tag125" decimals="-3" contextRef="D2011Q1" unitRef="USD">203000</us-gaap:InterestExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag126" decimals="-3" contextRef="D2011Q1" unitRef="USD">-3723000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:NetIncomeLoss id="Tag127" decimals="-3" contextRef="D2011Q1" unitRef="USD">-3723000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag128" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">-95964000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest id="Tag129" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">656000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense id="Tag130" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">8276000</us-gaap:InterestExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag131" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">-103584000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag132" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">-698000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="Tag133" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">-102886000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag134" decimals="2" contextRef="D2012Q1" unitRef="USDPerShare">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag135" decimals="-3" contextRef="D2012Q1" unitRef="USD">-8485000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag136" decimals="-3" contextRef="D2011Q1" unitRef="USD">-6150000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInContinuingOperations id="Tag137" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">14574000</us-gaap:NetCashProvidedByUsedInContinuingOperations>
  <path:ConversionOfNotePrincipalAndAccruedInterestToRedeemableConvertiblePreferredStock id="Tag138" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">4547000</path:ConversionOfNotePrincipalAndAccruedInterestToRedeemableConvertiblePreferredStock>
  <path:ConversionOfNotePrincipalAndAccruedInterestToCommonStock id="Tag139" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">10337000</path:ConversionOfNotePrincipalAndAccruedInterestToCommonStock>
  <us-gaap:ConversionOfStockAmountConverted1 id="Tag140" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">58072000</us-gaap:ConversionOfStockAmountConverted1>
  <path:ReclassificationOfWarrantLiability id="Tag141" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">1113000</path:ReclassificationOfWarrantLiability>
  <path:FairValueOfWarrantsIssuedInConnectionWithLoanFacility id="Tag142" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">272000</path:FairValueOfWarrantsIssuedInConnectionWithLoanFacility>
  <us-gaap:LiabilitiesAssumed1 id="Tag143" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">991000</us-gaap:LiabilitiesAssumed1>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment id="Tag144" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">9948000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:InterestPaid id="Tag145" decimals="-3" contextRef="D2012Q1" unitRef="USD">378000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="Tag146" decimals="-3" contextRef="D2011Q1" unitRef="USD">149000</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="Tag147" decimals="-3" contextRef="D2012Q1ITD" unitRef="USD">2470000</us-gaap:InterestPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag148" decimals="-3" contextRef="I2010" unitRef="USD">38918000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag149" decimals="-3" contextRef="I2011Q1" unitRef="USD">32768000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <dei:EntityRegistrantName id="Tag150" contextRef="D2012Q1">NUPATHE INC.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="Tag151" contextRef="D2012Q1">0001375200</dei:EntityCentralIndexKey>
  <dei:DocumentType id="Tag152" contextRef="D2012Q1">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate id="Tag153" contextRef="D2012Q1">2012-03-31</dei:DocumentPeriodEndDate>
  <dei:AmendmentFlag id="Tag154" contextRef="D2012Q1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag155" contextRef="D2012Q1">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory id="Tag156" contextRef="D2012Q1">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityCurrentReportingStatus id="Tag157" contextRef="D2012Q1">Yes</dei:EntityCurrentReportingStatus>
  <dei:DocumentFiscalYearFocus id="Tag158" contextRef="D2012Q1">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag159" contextRef="D2012Q1">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:EntityCommonStockSharesOutstanding decimals="INF" contextRef="I2012Q1SO" unitRef="Shares">14748582</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:RevenueFromGrants decimals="-3" contextRef="D2012Q1" unitRef="USD">0</us-gaap:RevenueFromGrants>
  <us-gaap:IncomeTaxExpenseBenefit decimals="-3" contextRef="D2012Q1" unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <path:CapitalFacilitiesDisclosureTextBlock contextRef="D2012Q1">&lt;table style="font-size:10pt; font-family:'Times New Roman',times,serif;"&gt;
&lt;tr&gt;
&lt;td&gt;
&lt;p style="TEXT-INDENT: 3pt; MARGIN: 0in 0in 0pt"&gt;&lt;b&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(4)&amp;#160;Capital Facilities&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 45pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(a)&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;Credit Facility and Vendor Debt&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 45pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;In May&amp;#160;2010, the Company executed a loan and security agreement with lenders to fund working capital requirements (the &amp;#8220;Term Loan Facility&amp;#8221;). The Company&amp;#8217;s obligations under the Term Loan Facility are secured by a lien on all of the Company&amp;#8217;s assets, excluding intellectual property, which is subject to a negative pledge prohibiting the granting of liens thereon to any third party. The Term Loan Facility also includes customary events of default including upon the occurrence of a payment default, a covenant default, a material adverse change (as defined therein) and insolvency. Upon the occurrence of an event of default, the interest on outstanding loans will be increased by 3% over the rate that would otherwise be applicable. In addition, the occurrence of an event of default could result in the acceleration of our obligations under the Term Loan Facility as well as grant the Lenders the right to exercise remedies with respect to the collateral.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Upon execution of the Term Loan Facility, the Company received $5,000 of loan proceeds (&amp;#8220;Term A Loans&amp;#8221;). The Company was required to make interest-only payments for the first twelve months of the Term A Loan&amp;#8217;s 39-month term; therefore at March&amp;#160;31, 2012, the balance of the Term A Loans was $3,148, with $2,222 of that amount being classified as current. The Term A Loans originally bore interest at an annual rate of LIBOR plus 8.75%, subject to a LIBOR floor of 3.00%. In June&amp;#160;2011, the interest rate was reduced to an annual rate of LIBOR plus 8.50%, subject to a LIBOR floor of 3.00%, in accordance with the amendment discussed below. The Term A Loans bear interest at 11.5% at March&amp;#160;31, 2012. In connection with the Term A Loans, the lenders received warrants to purchase 255,376 shares of Series&amp;#160;B preferred stock at $0.93 per share, which, upon the Company&amp;#8217;s IPO, converted into warrants to purchase 31,861 shares of common stock at $7.45 per share. The fair value of the warrants at the date of issuance of $204 was recorded as deferred financing costs and is being amortized to interest expense through the maturity date of the Term A Loans. As a result of the completion of the Company&amp;#8217;s IPO in August&amp;#160;2010, an additional $6,000 of funding became available to the Company under the Term Loan Facility (&amp;#8220;Term B Loans&amp;#8221;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;In June&amp;#160;2011, the Company and the lenders amended the Term Loan Facility to:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt; increase the amount of Term B Loans available to the Company from $6,000 to $10,000;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 27pt"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt; require the Company to maintain at least $3,000 of unrestricted cash, which cash requirement shall expire after the occurrence of an equity event resulting in unrestricted cash proceeds to the Company of at least $15,000; and&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0in 0in 0pt 27pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;font style="FONT-SIZE: 10pt" size="2"&gt; reduce the LIBOR rate margin for term loans under the facility from 8.75% to 8.50%.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;Concurrently with the amendment, the Company received $10,000 of Term B Loans (representing the total amount of Term B Loans available to the Company under the amended facility). The Company was required to make interest-only payments for the first six months of the Term B Loan&amp;#8217;s 26-month term; therefore at March&amp;#160;31, 2012, the balance of the Term B Loans was $8,500 with $6,000 of that amount being classified as current. The Term B Loans bear interest at an annual rate of LIBOR plus 8.50%, subject to a LIBOR floor of 3.00%. The Term B Loans bear interest at 11.5% at March&amp;#160;31, 2012.In connection with the Term B Loans, the lenders received warrants to purchase 59,748 shares of common stock at $7.95 per share. The fair value of the warrants at the date of issuance of $272 has been recorded as deferred financing costs and is being amortized to interest expense through the maturity date of the Term B Loans.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;In August&amp;#160;2011, the Company entered into two short-term agreements with third party vendors to finance insurance premiums.&amp;#160; The amount originally financed under the agreements was $532 and was later reduced to $401 due to a reduction of the Company&amp;#8217;s insurance premiums. These notes originally had a nine month term and an annual interest rate of 4.5%. In November&amp;#160;2011, one of the loans was paid in full, and as of March&amp;#160;31, 2012 the balance of the remaining short-term loan was $75, which is required to be repaid by May&amp;#160;2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 45pt"&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;(b)&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 3pt; FONT-WEIGHT: bold" size="1"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;i&gt;&lt;font style="FONT-STYLE: italic; FONT-SIZE: 10pt; FONT-WEIGHT: bold" size="2"&gt;Equity Facility&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 45pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt"&gt;&lt;font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" size="2"&gt;In August&amp;#160;2011, the Company entered into a common stock purchase agreement (&amp;#8220;Purchase Agreement&amp;#8221;) with Aspire Capital Fund,&amp;#160;LLC (&amp;#8220;Aspire Capital&amp;#8221;), which provides that Aspire Capital is committed to purchase up to an aggregate of $30,000 of the Company&amp;#8217;s common stock over the term of the Purchase Agreement. Upon execution of the Purchase Agreement, the Company issued 84,866 shares of common stock to Aspire Capital as a commitment fee in consideration for entering into the Purchase Agreement (the &amp;#8220;Commitment Shares&amp;#8221;) and the Company sold 70,721 shares of common stock to Aspire Capital at a per share purchase price of $7.07 resulting in gross proceeds to the Company of $500 (the &amp;#8220;Initial Purchase Shares&amp;#8221;). &lt;i&gt;&amp;#160;&lt;/i&gt;As of March&amp;#160;31, 2012, other than the Commitment Shares and Initial Purchase Shares referenced above, the Company has not made any sales to Aspire Capital.&amp;#160; In order to make future sales of common stock to Aspire Capital pursuant to the Purchase Agreement, the Company must first file, and have declared effective by the SEC, a post-effective amendment to the Company&amp;#8217;s S-1 registration statement (File No.&amp;#160;333-175987) covering Aspire Capital&amp;#8217;s sale of shares that are issued pursuant to the Purchase Agreement.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
</path:CapitalFacilitiesDisclosureTextBlock>
</xbrli:xbrl>